ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BAAT, bile acid-CoA:amino acid N-acyltransferase; Bile acid synthesis; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; ELF test, Enhanced Liver Fibrosis test; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; Fibroblast growth factor; Fibrogenesis; G/T ratio, ratio of glycine to taurine conjugates of bile acids; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; GLCA, glycolithocholic acid; LCA, lithocholic acid; MRI-PDFF, magnetic resonance imaging-proton density fat fraction; NAFLD, non-alcoholic fatty liver disease; NAS, non-alcoholic fatty liver disease activity score; NASH CRN, NASH Clinical Research Network; NASH, non-alcoholic steatohepatitis; Non-alcoholic steatohepatitis; PSC, primary sclerosing cholangitis; Primary sclerosing cholangitis; Pro-C3; Pro-C3, neoepitope-specific N-terminal pro-peptide of type III collagen; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TLCA, taurolithocholic acid; UDCA, ursodeoxycholic acid